News｜J-Pharma Co., Ltd.

Top＞News Lists

News Lists

Envalith Co., Ltd. to Initiate Research Coverage of J-Pharma

J-Pharma Establishes a Business Operations Department － Strengthening the Organizational Structure to Advance Partnerships and Related Activities for Pipeline Programs －

J-Pharma Decides on Policy to Expand Part A of the Global Phase III Beacon-BTC Study of Nanvuranlat to Japan and South Korea －Leveraging AMED Support to Reduce Financial Burden While Aiming to Generate Clinical Data and Build a Foundation for Future Development－

J-Pharma Holds Investigator Meeting to Prepare for Expansion of the Global Phase III Beacon-BTC Study of Nanvuranlat to Japan －Study Plan Shared with Prospective Investigators to Support the Conduct of the Study in Japan－

J-Pharma President and CEO Masuhiro Yoshitake Speaks at BioJapan 2026 Luncheon Seminar － Seminar Title: Real-World Lessons in Global Clinical Development and Market Expansion －

“J-Pharma Selected for Funding under AMED’s Global Research and Development Support Project for the Treatment of Intractable/Rare Diseases”

“J-Pharma Enters into Non-Binding Term Sheet with European Biotech Company for JPH034” — Aiming to Enter into a License Agreement for Global Development and Commercialization —

J-Pharma Transitions to an Executive Officer Structure as Development Pipeline Advances — Shinya Hirata Appointed as New Executive Officer —

J-Pharma’s LAT1 Inhibitor Development Included in University Office of Technology Commercialization’s FY2026 Annual Report — Report Highlights Progress in Clinical Development—

Post Hoc Analysis of Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer Published in Cancers — Exploratory Findings to Be Prospectively Evaluated in the Global Phase III Beacon-BTC Study —

1 2 3 4 5 6 7 8 9